Home Page / Exhibitors / Healthtech Solutions (HTS)

Healthtech Solutions (HTS)

New New products
Coralville, IA 52241
Booth(s):  9900-61


Health Tech Solutions (HTS) is a health-IT company that uses Artificial intelligent communication technology called TXP Chat™ to provide decision support for surgeons reviewing organ offers. Currently, 54% of donated organs go unused in the US every year. HTS is clinically live and facilitates the majority of organ transplants in Iowa and has expanded to 8 pilots throughout the U.S. HTS was awarded an NIH SBIR Phase I grant focused on using TXP Chat™ to maximize the number organs recovered per donor thereby reducing costs and increasing revenue for their hospital partners.

New Product/Service

TXP Chat™

Press Releases

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica} span.s1 {color: #0085cd}

Emerging health IT start-up HealthTech Solutions

has received a notice of award from the National Institutes of Health (NIH) for a Small

Business Innovation Research (SBIR) Phase I grant totaling $238,400. The grant will be

used to support research and development of the company’s proprietary software to

make organ transplant communication more efficient and effective.

Organ transplant is a complicated, time-sensitive process that relies on hundreds of

phone calls and faxes per donated organ. This inefficient communication contributes to

over 50 percent of available organs going to waste; meanwhile, 22 patients die each

day in the US waiting for a life-saving organ, over 120,000 people continue to wait for a

major organ transplant, with wait times up to five years.

The NIH granted only 526 out of over 4,000 SBIR Phase I applications in 2016, with

only three from Iowa, where HealthTech Solutions has its corporate base. Upon

completion of the Phase I SBIR project, Health Tech Solutions has the opportunity to

pursue an additional $1-2 million in grant funding via a NIH SBIR Phase II proposal.

“The SBIR grant program is incredibly competitive, and this award provides great

validation of the problem we are working to resolve as well as the positive impact that

our technology is likely to have on the transplant community,” said Dalton Shaull,

CEO/Co-Founder. “Having received an experimental transplant myself, I am passionate

about the field of organ transplantation, and our team is thrilled that our hard work has

paid off with a successful award.”